SCHEDULE: Comstock MultiChain Fund Increases Stake in BNB Plus Corp

Comstock MultiChain Fund has restructured its holdings in BNB Plus Corp through a warrant inducement agreement and initiated a strategic review of the company's business units.

Summary

• Comstock MultiChain Fund, L.P. and its affiliates now beneficially own 1,178,402 shares of BNB Plus Corp common stock, representing a 9.9% stake.
• The reporting persons exercised warrants from the October 2025 private placement and exchanged pre-funded warrants for new Series B-1 and B-2 preferred stock.
• An affiliate of the reporting persons has been engaged by the BNB Plus Corp board to conduct a strategic review of the company's biotech and digital asset treasury businesses.
• The holdings are subject to a 9.99% beneficial ownership limitation (the 'Blocker'), which currently excludes 13,024 shares of common stock underlying preferred stock and 2,462,052 shares underlying warrants from the reported total.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral-to-positive development; while the investor is increasing their stake and pushing for value-creation, the necessity of a strategic review suggests the company is currently facing operational or valuation challenges.

Positives

• Active engagement by a significant shareholder to drive strategic restructuring and unlock shareholder value.
• Conversion of warrants into preferred stock indicates long-term commitment to the issuer's capital structure.
• The company has secured an external strategic review of its core business segments, potentially leading to partnerships or M&A activity.

Negatives

• The 9.99% ownership blocker indicates that the investor is currently limited in its ability to increase its common stock position without triggering regulatory or contractual thresholds.
• The company is undergoing a complex restructuring of its warrants and preferred stock, which may signal previous capital structure challenges.

Risks

• The strategic review may result in recommendations that are not accepted by the board or that fail to materialize into value-accretive transactions.
• The issuer's financial position and market conditions remain key variables that could influence the reporting persons' future investment decisions.
• Potential for future dilution or changes in the capital structure as the reporting persons evaluate their position on a continuing basis.

Future Outlook

The reporting persons intend to review their investment on a continuing basis and may increase or decrease their position, or propose strategic transactions including combinations, partnerships, or investments following the completion of the strategic review.

Management Comments

• The reporting persons have been retained to conduct a strategic review of the Issuer's businesses, including its biotech business and its digital asset treasury business, with a view to consummating a restructuring or one or more strategic transactions to realize shareholder value.

Industry Context

StockSavvy.ai notes that the involvement of specialized investment funds in small-cap biotech and digital asset firms often precedes significant corporate restructuring or M&A activity, reflecting a trend of activist investors seeking to monetize undervalued business units.

Comparison to Industry Standards

• The use of 'Blocker' provisions at 9.99% is a standard practice in private placements for small-cap issuers to avoid triggering change-of-control provisions or regulatory reporting requirements.
• The engagement of a major shareholder to conduct a strategic review is a common mechanism in distressed or undervalued micro-cap companies to force management accountability.

Corporate Governance

Related Party Transactions

• The reporting persons are party to a Warrant Inducement Exchange Agreement with the Issuer.

Stakeholder Impact

• Shareholders may see increased volatility as the strategic review progresses.
• The potential for M&A or restructuring could significantly alter the company's future business model.

Next Steps

• Completion of the strategic review of the biotech and digital asset treasury businesses.
• Potential future adjustments to the reporting persons' position based on the outcome of the strategic review.
• Ongoing monitoring of the issuer's financial position and market conditions.

Key Dates

Recommendation

The stock is in a state of transition pending the outcome of the strategic review. Investors should hold until the board provides clarity on the direction of the biotech and digital asset business units.

Keywords

BNB Plus Corp, Schedule 13D, Comstock MultiChain Fund, Strategic Review, Biotech, Digital Asset Treasury, Warrant Inducement